Active Knowledge Translation for Chronic Kidney Disease

Phase-Based Progress Estimates
Southern Alberta Primary Care Research Network (SAPCReN), Calgary, CanadaChronic Kidney DiseaseActive Knowledge Translation - Other
All Sexes
What conditions do you have?

Study Summary

This trial will test whether providing patients with information about their risk of kidney failure improves quality of care, health literacy, and trust in the care they are receiving.

Eligible Conditions
  • Chronic Kidney Disease

Treatment Effectiveness

Study Objectives

2 Primary · 10 Secondary · Reporting Duration: 6 months after intervention

1 year after intervention
Appropriate medication usage
Appropriate referral for patients at high risk for kidney failure
Diabetes management for CKD patients
Hypertension management for CKD patients
Management of cardiovascular risk factors for CKD patients
Proportion of CKD patients in each clinic who have albuminuria (albumin-creatinine ratio (ACR)) tested
The percentage of patients who are appropriately managed with an ACEi or ARB, and who either have CKD and diabetes, or who have CKD and a urine ACR >30 mg/mmol.
Total Health Care Costs
2 years after intervention
eGFR function for CKD patients
6 months after intervention
Clinical provider's satisfaction with the risk prediction tools and clinical decision aids.
Patient's CKD-specific health literacy
Patient's trust in physician care

Trial Safety

Trial Design

2 Treatment Groups

Control Group
1 of 2
Active Knowledge Translation Group
1 of 2

Active Control

Experimental Treatment

6300 Total Participants · 2 Treatment Groups

Primary Treatment: Active Knowledge Translation · No Placebo Group · N/A

Active Knowledge Translation Group
Experimental Group · 1 Intervention: Active Knowledge Translation · Intervention Types: Other
Control GroupNoIntervention Group · 1 Intervention: Control Group · Intervention Types:

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 6 months after intervention

Who is running the clinical trial?

University of ManitobaLead Sponsor
545 Previous Clinical Trials
181,505 Total Patients Enrolled
Canadian Primary Care Sentinel Surveillance NetworkUNKNOWN
Canadians Seeking Solutions and Innovations to Overcome Chronic Kidney DiseaseOTHER
1 Previous Clinical Trials
2,500 Total Patients Enrolled
Manitoba Primary Care Research Network (MaPCReN)UNKNOWN
Southern Alberta Primary Care Research Network (SAPCReN)UNKNOWN
Navdeep Tangri, MD PhD FRCPCPrincipal InvestigatorUniversity of Manitoba
2 Previous Clinical Trials
110 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 2 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

Frequently Asked Questions

Are there any openings for individuals to join this experiment?

"The clinical trial is actively seeking volunteers; the initial posting was made on August 24th 2018, with a recent update seen on June 9th 2022." - Anonymous Online Contributor

Unverified Answer

What is the scope of enrollees for this experiment?

"Affirmative. According to, this trial is recruiting and was posted on August 24th 2018 with the latest edit occuring June 9th 2022. Approximately 6300 participants are sought from two separate medical facilities." - Anonymous Online Contributor

Unverified Answer

What objectives is this experiment seeking to accomplish?

"The principal outcome of this trial, to be evaluated within a year after the intervention, is the proportion of patients who are being treated adequately with ACEi or ARB and have either CKD and diabetes, or CKD plus urine ACR >30 mg/mmol. Subsidiary objectives include assessing clinical providers' satisfaction with risk prediction tools & decision aids (measured by Likert scale points), monitoring cardiovascular risk factors for CKD patients (proportion w/ statin prescription in EMR) & evaluating patient's kidney-related health literacy (number of KiKS survey answers)." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.